UCLA Jonsson Comprehensive Cancer Center researchers found that treating women with HER2 positive metastatic breast cancer with the HER2-targeting antibody-drug conjugate trastuzumab deruxtecan (T-DXd) significantly mitigates disease progression, compared to the current standard of care, trastuzumab emtansine (T-DM1).
In 1996, Lei Zheng, a graduate of Peking Union Medical College, enrolled in the doctorate program at what was then known as the Cancer Therapy & Research Center in San Antonio.
